文献速递白血病造血干细胞移植与细胞治疗

高危急性髓系白血病的造血干细胞移植结局:儿童肿瘤协作组报告

Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children's Oncology Group.
PubMed 文献 · J Clin Oncol · 2025-04-28

该研究合并AAML0531与AAML1031两项III期试验数据,比较首次完全缓解期造血干细胞移植与单纯化疗在重新定义的高危急性髓系白血病患儿中的结局。高危细胞遗传/分子异常组5年无病生存率移植组49.8% vs 化疗组26.0%(P<.001),标准风险细胞遗传/分子但诱导I结束时微小残留病阳性组移植组50.9% vs 化疗组16.9%(P=.032)。

要点

  • 高危细胞遗传/分子异常组5年无病生存率移植49.8% vs 化疗26.0%(P<.001)。
  • 标准风险细胞遗传/分子且MRD阳性组5年无病生存率移植50.9% vs 化疗16.9%(P=.032)。
  • 多因素分析及多数亚组中移植与结局改善相关,但7号或5号染色体缺失亚组例外。

核心结论

  • 在当代定义的高危急性髓系白血病患儿中,首次完全缓解期造血干细胞移植与结局改善相关。

研究设计与样本

  • 合并儿童肿瘤协作组(COG)已完成的两项III期临床试验AAML0531与AAML1031数据的跨研究分析。
  • 研究队列包括463例高危细胞遗传/分子异常患者和72例标准风险细胞遗传/分子结果但诱导I结束时微小残留病(MRD)阳性的患者。

主要发现

  • 高危细胞遗传/分子异常组中33.9%在首次完全缓解期接受造血干细胞移植,标准风险细胞遗传/分子且MRD阳性组中45.8%接受移植。
  • 高危细胞遗传/分子异常组5年无病生存率:化疗组26.0%(95% CI 20.6至31.6) vs 移植组49.8%(95% CI 41.7至57.4),P<.001。
  • 标准风险细胞遗传/分子且MRD阳性组5年无病生存率:化疗组16.9%(95% CI 4.3至36.7) vs 移植组50.9%(95% CI 32.7至66.5),P=.032。
  • 移植与两组患者复发减少及无病生存率改善相关。
  • 多因素分析及按临床试验和高危细胞遗传/分子亚型定义的各亚组中,移植均与结局改善相关,但7号或5号染色体缺失亚组例外。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Hematopoietic stem cell transplantation (HSCT) is used as consolidation for pediatric patients with high-risk AML in first complete remission (CR1). The definition of high-risk AML has evolved considerably over the past two decades with the successive identification of new unfavorable risk factors. We conducted a cross-study analysis to determine whether HSCT improves the outcomes of patients with contemporarily defined high-risk AML. METHODS: We combined data from AAML0531 and AAML1031, the last two phase III clinical trials completed by the Children's Oncology Group (COG). These two trials established the prognostic importance of measurable residual disease (MRD) and several high-risk cryptic cytogenetic/molecular (CM) alterations, which were applied to reclassify patients in the current COG phase III clinical trial, AAML1831. We compared the outcomes after HSCT in CR1 with those after chemotherapy alone in CR1 in the redefined high-risk group. RESULTS: Our study cohort comprised 463 patients with high-risk CM alterations and 72 patients with standard-risk (SR) CM results with positive MRD at end of induction I. In all, 33.9% and 45.8% of these groups underwent HSCT in CR1, respectively. HSCT was associated with decreased relapse and improved disease-free survival (DFS) in both groups. In the high-risk CM group, 5-year DFS was 26.0% (95% CI, 20.6 to 31.6) and 49.8% (95% CI, 41.7 to 57.4; P < .001) in patients receiving chemotherapy alone and HSCT, respectively. In the SR CM and MRD+ groups, DFS was 16.9% (95% CI, 4.3 to 36.7) compared with 50.9% (95% CI, 32.7 to 66.5; P = .032). HSCT was also associated with improvement in outcomes based on multivariable analysis and across subgroups defined by clinical trial and by high-risk CM subtype, with the exception of chromosome 7 or 5 loss. CONCLUSION: HSCT was associated with improved outcomes in pediatric patients with contemporarily defined high-risk AML.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Huang BJ, Meyer LK, Alonzo TA, et al. Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children's Oncology Group. J Clin Oncol. 2025. PMID: 40294366. doi:10.1200/JCO-24-01841

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。